Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.6%

8 terminated/withdrawn out of 105 trials

Success Rate

88.1%

+1.6% vs industry average

Late-Stage Pipeline

37%

39 trials in Phase 3/4

Results Transparency

0 of 59 completed trials have results

Key Signals

7 recruiting8 terminated

Enrollment Performance

Analytics

Phase 2

35(38.9%)

Phase 4

25(27.8%)

Phase 3

14(15.6%)

Phase 1

12(13.3%)

N/A

4(4.4%)

90Total

Phase 2(35)

Phase 4(25)

Phase 3(14)

Phase 1(12)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (105)

Showing 20 of 105 trials

NCT07107529Phase 2Recruiting

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Role: collaborator

NCT07507760Phase 2Not Yet Recruiting

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

Role: lead

NCT04107727Phase 2Completed

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Role: lead

NCT07478991Phase 3Not Yet Recruiting

Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)

Role: lead

NCT04802356Phase 2Active Not Recruiting

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Role: lead

NCT07443592Not ApplicableNot Yet Recruiting

Treatment for Ph-negative ALL for Adults up to 65 Years

Role: lead

NCT03589222Phase 2Active Not Recruiting

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Role: lead

NCT07045909Phase 2Recruiting

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

Role: lead

NCT05849610Phase 2Active Not Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Role: lead

NCT04178798Phase 3Completed

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

Role: lead

NCT04090736Phase 3Active Not Recruiting

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Role: lead

NCT06574126Phase 2Recruiting

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

Role: lead

NCT06544785Phase 2Recruiting

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Role: lead

NCT06282978Phase 2Recruiting

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Role: lead

NCT06175702Not Yet Recruiting

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

Role: lead

NCT05558319Phase 3Not Yet Recruiting

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Role: lead

NCT03280160Phase 2Unknown

Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Role: lead

NCT05218603Unknown

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Role: lead

NCT05541224Completed

A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic Markers

Role: lead

NCT03742297Phase 3Active Not Recruiting

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Role: lead